Drug-induced lung injury

Seminars in Roentgenology

Volumn 37, Issue 1, 2002, Pages 72-81

  Erasmus, Jeremy J ^a,b,c   Page McAdams, H ^a,b,c   Rossi, Santiago E ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Fundacion Dr Enrique Rossi ^*  (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPHOTERICIN B; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GOLD SALT; HYDROCHLOROTHIAZIDE; MELPHALAN; METHOTREXATE; MITOMYCIN; NAVELBINE; NITROFURANTOIN; OPIATE; PACLITAXEL; PENICILLAMINE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TOPOTECAN; TRICYCLIC ANTIDEPRESSANT AGENT; VINBLASTINE;

BRONCHIOLITIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FIBROSING ALVEOLITIS; HUMAN; LUNG EDEMA; LUNG INJURY; PNEUMONIA; PRIORITY JOURNAL; REVIEW;

EID: 0036105092     PISSN: 0037198X     EISSN: None     Source Type: Journal    
DOI: 10.1053/sroe.2002.0000     Document Type: Article

References (73)

1. Drug-induced pulmonary disease. An update
2. Drug-induced lung disease: 1990 Review
3. Drug-induced pulmonary disease
4. Drug-induced pulmonary disorders
5. Pathologic mechanisms of drug-induced lung disorders
6. The histopathology of pulmonary reactions to drugs
7. Radiographic patterns of drug-induced lung diseases
8. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs
9. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs
10. Drug-induced lung disease
11. Drug-induced noncardiogenic pulmonary edema
12. Drug-induced pulmonary disease
13. Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia
14. Pulmonary complications of cancer therapy
15. Reactivation of bleomycin lung toxicity following oxygen administration. A second response to corticosteroids
16. Pathology of drug-induced lung disease
17. Drug-induced lung disease
18. Amiodarone lung: Pathologic findings in clinically toxic patients
19. Amiodarone pulmonary toxicity: CT findings in symptomatic patients
20. Pulmonary toxicity in long-term administration of BCNU
21. Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: Classification and diagnostic criteria
22. Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations
23. Nonspecific interstitial pneumonia with fibrosis: High-resolution CT and pathologic findings
24. Bronchiolitis obliterans organizing pneumonia
25. The alphabet soup revisited: The chronic interstitial pneumonias in the 1990s
26. The spectrum of eosinophilic lung disease: Radiologic findings
27. Diffuse pulmonary hemorrhage: Clinical, pathologic, and imaging features
28. Methotrexate-induced pneumonitis
29. Lung toxicity associated with cyclophosphamide use. Two distinct patterns
30. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
31. Gemcitabine pulmonary toxicity: CT features
32. Gemcitabine safety overview
33. Etoposide-induced pulmonary toxicity
34. Hypersensitivity reactions induced by etoposide
35. Pulmonary infiltrates following administration of paclitaxel
36. The taxoids. Comparative clinical pharmacology and therapeutic potential
37. Pulmonary toxicity of mitomycin
38. Early-onset cyclophosphamide-induced interstitial pneumonitis
39. Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide
40. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation
41. The pulmonary toxicity of antineoplastic agents
42. Additive pulmonary toxicity with melphalan and busulfan therapy
43. Busulphan lung
44. Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia
45. Effects of long-term administration of busulfan. Report of a patient with generalized nuclear abnormalities, carcinoma of vulva, and pulmonary fibrosis
46. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: An assessment of risk factors
47. Early pulmonary toxicity after administration of high-dose BCNU
48. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU)
49. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: Pharmacodynamic evaluation of carmustine
50. Rapidly progressive, fatal pulmonary fibrosis induced by carmustine
51. Late carmustine lung fibrosis. Age at treatment may influence severity and survival
52. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood
53. Fatal pulmonary reaction from low doses of bleomycin. An idiosyncratic tissue response
54. Reversible interstitial pneumonitis associated with low dose bleomycin
55. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients
56. Cytotoxic drug-induced lung injury
57. Bleomycin hypersensitivity pneumonitis
58. Drug-induced pulmonary disease
59. Multiple pulmonary nodules: Unusual manifestation of bleomycin toxicity
60. Methotrexate therapy and pulmonary disease
61. Methotrexate pulmonary toxicity
62. Chemical pleuritis as the cause of acute chest pain following high-dose methotrexate treatment
63. Pleurisy and methotrexate treatment
64. Optimal management of amiodarone therapy: Efficacy and side effects
65. Mechanisms of amiodarone pulmonary toxicity
66. Clinical aspects of amiodarone pulmonary toxicity
67. Amiodarone pulmonary toxicity: A multidisciplinary review of current status
68. Hospitalizations for pulmonary reactions following nitrofurantoin use
69. Nitrofurantoin-induced pulmonary toxicity during pregnancy: A report of a case and review of the literature
70. Non fatal pulmonary haemorrhage associated with nitrofurantoin
71. High-resolution computed tomography of drug-induced lung disease
72. Drugs that may injure the respiratory system
73. Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin